RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Clovis Oncology Stock

Clovis Oncology Employees 2025

Clovis Oncology Employees

0

Ticker

C6O.F

ISIN

US1894641000

WKN

A1JPJY

In 2025, Clovis Oncology employed 0 people, a 0% change from the 0 number of employees in the previous year.

Clovis Oncology Aktienanalyse

What does Clovis Oncology do?

Clovis Oncology Inc. is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. The company is based in Boulder, Colorado and was founded in 2009. They focus on researching and developing innovative therapies for cancer patients. History: Clovis Oncology was founded by Patrick Mahaffy and his team, who previously worked at Pharmion Corporation and sold the biotech company to Celgene. After the sale of Pharmion, Mahaffy and his colleagues wanted to build something new and started Clovis Oncology. Clovis started its activities in 2009 and initially focused on the development of PARP inhibitors, which can be used for the treatment of breast and ovarian cancer. In 2011, the company conducted Phase I studies with its leading product candidate, Rucaparib. Business model: Clovis Oncology has a business model based on the discovery, development, and commercialization of innovative cancer therapies. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a global network of research and development facilities that allows them to focus on the therapy areas where they are best positioned. Through partnerships and licenses, the company also has access to specialized technologies and expertise in cancer research. Divisions: Clovis Oncology is divided into two divisions: 1. Research and development: Clovis operates an intensive research and development program focused on the discovery and development of new cancer therapies. The focus is on developing PARP inhibitors that offer new treatments for breast and ovarian cancer. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a strong pipeline of products in various stages of clinical development. 2. Commercialization: Clovis also has an experienced marketing team responsible for the marketing and distribution of Rucaparib. Rucaparib is a PARP inhibitor approved for the treatment of breast and ovarian cancer in the United States and several other countries. Products: The main product of Clovis Oncology is Rucaparib, a PARP inhibitor for the treatment of breast and ovarian cancer. The medication was approved by the US Food and Drug Administration (FDA) in December 2016 for use in patients with advanced ovarian cancer. Clovis also has a pipeline of products in various stages of clinical development. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Summary: Clovis Oncology is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. They have a focus on developing PARP inhibitors and currently offer Rucaparib for the treatment of breast and ovarian cancer. Clovis has a strong pipeline of products in various stages of clinical development and collaborates closely with academic institutions and other companies to advance cancer research. Clovis Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Clovis Oncology's Employee Base

Clovis Oncology's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Clovis Oncology's operational capacity and future potential.

Year-to-Year Comparison

Assessing Clovis Oncology's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Clovis Oncology's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Clovis Oncology’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Clovis Oncology stock

How many employees does Clovis Oncology have this year?

Clovis Oncology has 0 undefined employees this year.

How many employees did Clovis Oncology have compared to the previous year?

Compared to the previous year, Clovis Oncology had 0% more employees.

What impact did the number of employees have on the company Clovis Oncology?

The number of employees has a direct impact on the efficiency and productivity of Clovis Oncology. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Clovis Oncology?

The number of employees can also have an impact on investors of Clovis Oncology, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Clovis Oncology affect the company?

An increase in equity of Clovis Oncology can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Clovis Oncology's equity affect the company?

A reduction in equity of Clovis Oncology can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Clovis Oncology?

Some factors that can influence the equity of Clovis Oncology include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Clovis Oncology so important for investors?

The equity of Clovis Oncology is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Clovis Oncology influence the company?

The number of employees at Clovis Oncology can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Clovis Oncology evolved in recent years?

In recent years, the number of employees at Clovis Oncology has changed by NaN.

How many employees does Clovis Oncology currently have?

Clovis Oncology currently has 0 undefined employees.

Why is the number of employees important for investors of Clovis Oncology?

The number of employees is important for investors of Clovis Oncology as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Clovis Oncology take to change the number of employees?

To change the number of employees, Clovis Oncology can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Clovis Oncology pay?

Over the past 12 months, Clovis Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Clovis Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Clovis Oncology?

The current dividend yield of Clovis Oncology is .

When does Clovis Oncology pay dividends?

Clovis Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Clovis Oncology?

Clovis Oncology paid dividends every year for the past 0 years.

What is the dividend of Clovis Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Clovis Oncology located?

Clovis Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clovis Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clovis Oncology from 4/29/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/29/2025.

When did Clovis Oncology pay the last dividend?

The last dividend was paid out on 4/29/2025.

What was the dividend of Clovis Oncology in the year 2024?

In the year 2024, Clovis Oncology distributed 0 USD as dividends.

In which currency does Clovis Oncology pay out the dividend?

The dividends of Clovis Oncology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Clovis Oncology stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Clovis Oncology

Our stock analysis for Clovis Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clovis Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.